Nissinen Jari, Pitkänen Asla
A.I. Virtanen Institute, University of Kuopio, P.O. Box 1627, FIN-70 211 Kuopio, Finland.
Epilepsy Res. 2007 Feb;73(2):181-91. doi: 10.1016/j.eplepsyres.2006.10.003. Epub 2006 Dec 11.
The present study investigated whether spontaneously seizing animals are a valid model for evaluating antiepileptic compounds in the treatment of human epilepsy. We examined whether clinically effective antiepileptic drugs (AEDs), including carbamazepine (CBZ), valproic acid (VPA), ethosuximide (ESM), lamotrigine (LTG), or vigabatrin (VGB) suppress spontaneous seizures in a rat model of human temporal lobe epilepsy, in which epilepsy is triggered by status epilepticus induced by electrical stimulation of the amygdala. Eight adult male rats with newly diagnosed epilepsy and focal onset seizures were included in the study. Baseline seizure frequency was determined by continuous video-electroencephalography (EEG) monitoring during a 7 days baseline period. This was followed by a 2-3 days titration period, a 5-7 days treatment period, and a 2-3 days wash-out period. During the 5-7 days treatment period, animals were treated successively with CBZ (120 mg/kg/day), VPA (600 mg/kg/day), ESM (400 mg/kg/day), LTG (20 mg/kg/day), and VGB (250 mg/kg/day). VPA, LTG, and VGB were the most efficient of the compounds investigated, decreasing the mean seizure frequency by 83, 84, and 60%, respectively. In the VPA group, the percentage of rats with a greater than 50% decrease in seizure frequency was 100%, in the LTG group 88%, in the VGB group 83%, in the CBZ group 29%, and in the ESM group 38%. During the 7 day treatment period, 20% of the VPA-treated animals and 14% of the CBZ-treated animals became seizure-free. These findings indicate that rats with focal onset spontaneous seizures respond to the same AEDs as patients with focal onset seizures. Like in humans, the response to AEDs can vary substantially between animals. These observations support the idea that spontaneously seizing animals are a useful tool for testing novel compounds for the treatment of human epilepsy.
本研究调查了自发性癫痫发作的动物是否是评估抗癫痫化合物治疗人类癫痫的有效模型。我们研究了包括卡马西平(CBZ)、丙戊酸(VPA)、乙琥胺(ESM)、拉莫三嗪(LTG)或氨己烯酸(VGB)在内的临床有效抗癫痫药物(AEDs)是否能抑制人类颞叶癫痫大鼠模型中的自发性癫痫发作,该模型中癫痫由杏仁核电刺激诱导的癫痫持续状态引发。研究纳入了8只新诊断为癫痫且有局灶性发作的成年雄性大鼠。通过在7天的基线期进行连续视频脑电图(EEG)监测来确定基线癫痫发作频率。随后是2 - 3天的滴定期、5 - 7天的治疗期和2 - 3天的洗脱期。在5 - 7天的治疗期内,动物依次接受CBZ(120 mg/kg/天)、VPA(600 mg/kg/天)、ESM(400 mg/kg/天)、LTG(20 mg/kg/天)和VGB(250 mg/kg/天)治疗。VPA、LTG和VGB是所研究化合物中最有效的,分别使平均癫痫发作频率降低了83%、84%和60%。在VPA组中,癫痫发作频率降低超过50%的大鼠百分比为100%,LTG组为88%,VGB组为83%,CBZ组为29%,ESM组为38%。在7天的治疗期内,20%接受VPA治疗的动物和14%接受CBZ治疗的动物癫痫发作停止。这些发现表明,局灶性发作的自发性癫痫大鼠对与局灶性发作患者相同的AEDs有反应。与人类一样,动物之间对AEDs的反应可能有很大差异。这些观察结果支持了自发性癫痫发作的动物是测试治疗人类癫痫新化合物的有用工具这一观点。